English 
Español
Validation of an ADCC assay using human primary natural killer cells to evaluate biotherapeutic products bearing an Fc región.
Related Articles
-
UDIBI
Colloids and Surfaces A: Physicochemical and Engineering Aspects. Structural and physicochemical characteristics of one-step PAMAM dendrimeric nanoparticles. SHOW MORE
-
UDIBI
Published: September 6, 2022 In Vitro and In Vivo Characterization of a Broadly Neutralizing Anti-SARS-CoV-2 Antibody Isolated from a...
-
-
UDIBI
November 8, 22 Altered neutrophil-to-lymphocyte ratio in sepsis secondary to canine parvoviral enteritis treated with and without an immunomodulator...
-
UDIBI
Development of Functional Antibodies Directed to Human Dialyzable Leukocyte Extract (Transferon®). SHOW MORE
-
UDIBI
Validation of a cell proliferation assay to assess the potency of a Dialyzable Leucocyte Extract intended for batch release....
-
UDIBI
Identity Profiling of Complex Mixtures of Peptide Products by Structural and Mass Mobility Orthogonal Analysis. SHOW MORE
-
UDIBI
Taking advantage of a high-throughput flow cytometer for the implementation of an ADCC assay for regulatory compliance. SHOW MORE
